BTK and plasma cell neoplasm: Zanubrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, has shown efficacy in IgM-driven plasma cell disorders and was used in this case due to the patient's age, comorbidities, and high IgM burden.